Tumor Neoantigen Heterogeneity Thresholds Provide a Time Window for Combination Immunotherapy

doi 10.1101/823856
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Cold Spring Harbor Laboratory

Related search

A Bi-Adjuvant Nanovaccine That Potentiates Immunogenicity of Neoantigen for Combination Immunotherapy of Colorectal Cancer

Science advances
Multidisciplinary
2020English

Primary 4T1 Tumor Resection Provides Critical “Window of Opportunity” for Immunotherapy

Clinical and Experimental Metastasis
MedicineCancer ResearchOncology
2013English

Single-Cell Analysis of Circulating Tumor Cells as a Window Into Tumor Heterogeneity

Cold Spring Harbor Symposia on Quantitative Biology
BiochemistryGeneticsMolecular Biology
2016English

Tumor Burden Affects Efficacy of Combination Immunotherapy

Cancer Discovery
Oncology
2019English

Combination Immunotherapy for Melanoma

JAMA Oncology
Cancer ResearchOncology
2015English

Addressing Genetic Tumor Heterogeneity Through Computationally Predictive Combination Therapy

Cancer Discovery
Oncology
2013English

Tumor Targeted Nanocarriers for Immunotherapy

Molecules
Organic ChemistryMolecular MedicineAnalytical ChemistryTheoretical ChemistryPharmaceutical ScienceMedicineDrug DiscoveryChemistryPhysical
2020English

Extending the Time Window for Thrombolysis

International Journal of Stroke
Neurology
2019English

MS21.06 Immunotherapy - Sequence or Combination?

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy